AEYE Health

Executive Summary

AEYE Health is a pioneering digital health company headquartered in Tel Aviv, with a strong presence in the United States. Founded in 2018, the company specializes in fully autonomous, AI-based diagnostic screening solutions for retinal imaging. Their flagship technology enables point-of-care screening for diabetic retinopathy, a leading cause of blindness, by providing accurate, accessible, and practical diagnostics. AEYE Health's AI algorithms deliver best-in-class results, allowing for rapid detection without the need for a specialist on-site, thereby expanding access to care, especially in underserved areas. The company operates in the diagnostics category and is currently privately held, with no disclosed funding or valuation data. Despite being in a competitive landscape, AEYE Health's unique value proposition lies in its fully autonomous screening capability, which differentiates it from semi-automated competitors. The company is well-positioned to capture market share as healthcare systems increasingly adopt AI-driven diagnostic tools to improve efficiency and patient outcomes. Key upcoming catalysts include potential FDA clearance for expanded indications, strategic partnerships with large healthcare providers or payers, and subsequent commercialization efforts. These events could significantly accelerate adoption and drive revenue growth, making AEYE Health an attractive prospect for investors focused on AI in healthcare diagnostics.

Upcoming Catalysts (preview)

• Q4 2026FDA Clearance for Expanded Retinal Screening Indications70% success
• Q1 2027Strategic Partnership with Major Healthcare Provider or Payer60% success
• H1 2027Series B or Series C Funding Round65% success